Table 3.
Logistic regression analysis to determine variables associated with dapagliflozin responders (relative HbA1c reduction ≥ 10%) in 12 weeks
| Variable | Odds ratio | 95% CI | P value |
|---|---|---|---|
| Univariate | |||
| Age, years | 0.99 | 0.98–0.99 | 0.003 |
| Sex, male | 1.26 | 1.06–1.51 | 0.011 |
| Diabetes duration (≥ 24 months) | 0.41 | 0.32–0.54 | < 0.001 |
| Baseline BMI, kg/m2 | 0.97 | 0.95–0.99 | 0.013 |
| Baseline SBP, mmHg | 1.01 | 1.00–1.01 | 0.140 |
| Baseline HbA1c, % | 2.31 | 2.11–2.54 | < 0.001 |
| Baseline FPG, mg/dl | 1.01 | 1.01–1.02 | < 0.001 |
| Baseline PPG, mg/dl | 1.01 | 1.01–1.01 | < 0.001 |
| Baseline creatinine, mg/dl | 0.56 | 0.33–0.95 | 0.031 |
| Baseline eGFR | 1.01 | 1.01–1.02 | < 0.001 |
| Anti-diabetic medication, add-on | 2.49 | 2.07–3.01 | < 0.001 |
| Multivariate | |||
| Age (≥ 50 years) | 0.71 | 0.47–1.09 | 0.116 |
| Sex, male | 1.19 | 0.80–1.78 | 0.385 |
| Diabetes duration (≥ 24 months) | 0.46 | 0.30–0.69 | 0.001 |
| Baseline BMI (≥ 25 kg/m2) | 0.72 | 0.45–1.16 | 0.175 |
| Baseline HbA1c, % | 3.12 | 2.48–3.92 | < 0.001 |
| Baseline eGFR, (≥ 90 ml/min/m2) | 0.98 | 0.63–1.53 | 0.923 |
| Anti-diabetic medication, add-on | 2.71 | 1.72–4.27 | < 0.001 |
BMI body mass index, SBP systolic blood pressure, HbA1c glycated hemoglobin, FPG fasting plasma glucose, PPG postprandial glucose, eGFR estimated glomerular filtration rate